Firefly BioWorks, Inc., a Cambridge, MA-based developer of instrument-independent multiplexed assays, has closed a $2m financing.
The company intends to use the funding to execute its commercial strategy, by launching an early access program with leading academic and industrial partners.
Led by co-founder and CEO Dr. Davide Marini, Firefly BioWorks is introducing an open platform allowing industrial, academic and clinical scientists to develop and use multiplexed biological assays on standard laboratory instrumentation. The company’s core technology, Optical Liquid Stamping, was developed in the Chemical Engineering Department at MIT by Firefly co-founders.
The method allows rapid and scalable synthesis of encoded, multi-functional particles for the quantification of biological function.